The high comorbidity burden of the hepatitis C virus infected population in the United States

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Louie, Karly S ^a   St Laurent, Samantha ^b   Forssen, Ulla M ^b   Mundy, Linda M ^b   Pimenta, Jeanne M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BENIGN TUMOR; CHILD; COHORT ANALYSIS; COMORBIDITY; CONCENTRATION LOSS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; GOUT; HAIR DISEASE; HAIR THINNING; HEARING LOSS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFANT; INSOMNIA; IRRITABILITY; LIVER DISEASE; LOWER RESPIRATORY TRACT; LOWER RESPIRATORY TRACT DISEASE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; POPULATION RESEARCH; PRESCHOOL CHILD; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN IRRITATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; TINNITUS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VIRUS INFECTION; VISUAL DISORDER; WEIGHT REDUCTION; AGED; MIDDLE AGED; NEWBORN; PREVALENCE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84859502539     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-86     Document Type: Article

References (36)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. 10.1002/hep.22759, 19330875.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338. 10.1053/jlts.2003.50073, 12682882.
4. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002, 36(Suppl 1):S30-S34.
5. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006, 44(Suppl 1):S19-S24.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 Practice guideline by the american association for the study of liver diseases. Hepatology 2011, 54:1433-1444. 10.1002/hep.24641, 3229841, 21898493.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171. 10.1002/hep.20119, 15057920.
8. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(Suppl 1):S237-S244.
9. Elixhauser A, Palmer L. Clinical Classification Softward (CCS), 2006. US Agency for Healthcare Reseach and Quality. , http://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp
10. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chroni Dis 1970, 23:455-468.
11. Centers for Disease and Control and Prevention FAQs for the public. Centers for Disease and Control and Prevention 2010. [cited 2010 May 2], Centers for Disease and Control and Prevention., http://www.cdc.gov/hepatitis/C/cFAQ.htm#cFAQ15
12. NIH NIH consensus statement on management of Hepatitis C. NIH Consens State Sci Statements 2002, 19:1-46. NIH.
13. Parrilli G, Manguso F, Orsini L, Coccoli P, Vecchione R, Terracciano L, De Luca N, Cirillo N, Abazia C, Budillon G, Marchesini G. Essential hypertension and chronic viral hepatitis. Dig Liver Dis 2007, 39:466-472. 10.1016/j.dld.2007.01.009, 17369113.
14. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent KC. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007, 14:890-896.
15. Magana M, Gomez LM. Skin metastasis from hepatocarcinoma. Am J Dermatopathol 2009, 31:502-505. 10.1097/DAD.0b013e31819d095e, 19542932.
16. Reisacher WR. Prevalence of autoimmune thyroid disease in chronic rhinitis. Ear Nose Throat J 2008, 87:524-527.
17. Hoffman-La Roche Inc Medication Guide: Pegasys (peg-interferon alfa-2a), 2008. Accessed 10 July 2010, Hoffman-La Roche Inc., http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf
18. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010, 21:33-40. 10.1016/j.tem.2009.07.005, 2818172, 19854061.
19. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009, 104:1802-1829. 10.1038/ajg.2009.191, 19455106.
20. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005, 3:311-318. 10.1016/S1542-3565(04)00666-4, 15822034.
21. Markowitz JS, Gutterman EM, Hodes D, Klaskala W. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005, 12:176-185. 10.1111/j.1365-2893.2005.00607.x, 15720533.
22. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002, 34:268-271. 10.1097/00004836-200203000-00015, 11873110.
23. Schiffman ML. A balancing view: we cannot do it alone. Am J Gastroenterol 2007, 102:1841-1843. 10.1111/j.1572-0241.2007.01433_4.x, 17727427.
24. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755. 10.1002/hep.23220, 19824079.
25. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001, 345:215-217. 10.1056/NEJM200107193450312, 11463020.
26. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573. 10.1086/600304, 19589081.
27. Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000, 216:698-703.
28. El Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002, 36:1439-1445.
29. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008, 21:813-825.
30. Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011, 18:134-143.
31. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011, 53:737-745. 10.1002/hep.24131, 21319199.
32. Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Res Hum Retroviruses 2011,
33. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010, 30:240-250. 10.1111/j.1478-3231.2009.02156.x, 3132089, 19889081.
34. Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis. J Clin Gastroenterol 2008, 42:1054-1059. 10.1097/MCG.0b013e3181574d58, 19013829.
35. Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans. J Clin Gastroenterol 2007, 41:322-328. 10.1097/01.mcg.0000225629.22286.96, 17426475.
36. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, Carioti J, Maio G, Monarca R, Antinori A, . Nocchiero Study Group Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007, 102:423-431. 10.1111/j.1360-0443.2006.01698.x, 17298650, Nocchiero Study Group.